234 related articles for article (PubMed ID: 23208700)
1. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.
Sörensen J; Owenius R; Lax M; Johansson S
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):394-402. PubMed ID: 23208700
[TBL] [Abstract][Full Text] [Related]
2. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
3. Phase IIa clinical study of [
Kondo A; Ishii H; Aoki S; Suzuki M; Nagasawa H; Kubota K; Minamimoto R; Arakawa A; Tominaga M; Arai H
Ann Nucl Med; 2016 Nov; 30(9):608-618. PubMed ID: 27418267
[TBL] [Abstract][Full Text] [Related]
4. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
[TBL] [Abstract][Full Text] [Related]
5. Comparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats.
Kanagawa M; Doi Y; Oka S; Kobayashi R; Nakata N; Toyama M; Shirakami Y
Nucl Med Biol; 2014 Aug; 41(7):545-51. PubMed ID: 24816330
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
[TBL] [Abstract][Full Text] [Related]
8. Characterising
Scott NP; Teoh EJ; Flight H; Jones BE; Niederer J; Mustata L; MacLean GM; Roy PG; Remoundos DD; Snell C; Liu C; Gleeson FV; Harris AL; Lord SR; McGowan DR
Br J Cancer; 2022 Mar; 126(4):598-605. PubMed ID: 34795409
[TBL] [Abstract][Full Text] [Related]
9. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
10. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
11. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
[TBL] [Abstract][Full Text] [Related]
12.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [
Akintayo AA; Abiodun-Ojo OA; Weber C; Sharma J; Cohen C; Sica G; Halkar R; Goodman MM; Schuster DM
Mol Imaging Biol; 2019 Oct; 21(5):818-824. PubMed ID: 30617729
[TBL] [Abstract][Full Text] [Related]
15. Review of
Gusman M; Aminsharifi JA; Peacock JG; Anderson SB; Clemenshaw MN; Banks KP
Radiographics; 2019; 39(3):822-841. PubMed ID: 31059396
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
[TBL] [Abstract][Full Text] [Related]
17. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan.
Gill HS; Tade F; Greenwald DT; Yonover PM; Savir-Baruch B
Clin Nucl Med; 2018 Jan; 43(1):23-24. PubMed ID: 29189374
[TBL] [Abstract][Full Text] [Related]
19. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
20. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
[Next] [New Search]
